Drug · CHEMBL799
CILOSTAZOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CILOSTAZOL. Drugs and targets, record CHEMBL799. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL799
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PDE3A | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A | Phosphodiesterase 3A inhibitor | INHIBITOR | https://conductscience.org/library/genes/5139 |
Source ChEMBL
Diseases32
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 32Source Open Targets
See all 32 diseasesTrials155
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00234065 | Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) | Phase 4 | 2,800 | 2011-05-13 | cilostazol | Its name | ClinicalTrials.gov |
| NCT00130039 | Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II | Phase 4 | 457 | 2010-01-01 | cilostazol | Its name | ClinicalTrials.gov |
| NCT03451591 | LACunar Intervention (LACI-2) Trial-2 | Phase 2/3 | 363 | 2024-11-12 | cilostazol | Its name | ClinicalTrials.gov |
| NCT00446641 | Overcome Biochemical Aspirin Resistance Through Cilostazol Combination | Phase 4 | 244 | 2010-01-18 | cilostazol | Its name | ClinicalTrials.gov |
| NCT00741286 | Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler | Phase 4 | 203 | 2011-09-05 | cilostazol | Its name | ClinicalTrials.gov |
| NCT00822172 | Evaluation of Cilostazol in Combination With L-Carnitine | Phase 4 | 164 | 2013-05-22 | cilostazol | Its name | ClinicalTrials.gov |
| NCT02554721 | Pharmacodynamic Study of Cilostazol in Healthy Volunteers | Phase 1 | 77 | 2021-10-13 | cilostazol | Its name | ClinicalTrials.gov |
| NCT01409564 | Cilostazol Augmentation Study in Dementia | Phase 4 | 46 | 2014-05-13 | cilostazol | Its name | ClinicalTrials.gov |
| NCT00838630 | Cilostazol 100 mg Tablet Formulations Under Fasting Conditions | Phase 1 | 36 | 2009-07-21 | cilostazol | Its name | ClinicalTrials.gov |
| NCT00684762 | Fasted Bioavailability Study of Cilostazol Tablets, 100 mg | Phase 1 | 32 | 2009-12-22 | cilostazol | Its name | ClinicalTrials.gov |
1 to 10 of 155
See all 155 trialsComparisons in its trials32
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pentoxifylline vs Cilostazol: deaths from any cause | 0 of 1,687 | 0 of 1,687 | 3,374 | NCT05635370 | Trial comparisons |
| Cilostazol vs Aspirin: Number of Patients With First Recurrence of Cerebral Infarction | 72 of 1,337 | 88 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Aspirin: Number of Patients With First Occurrence of Haemorrhagic Event | 23 of 1,337 | 57 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Aspirin: Numbers of Patients With First Occurence of Stroke | 82 of 1,337 | 119 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Aspirin: Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease | 86 of 1,337 | 103 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Aspirin: Number of Deaths From Any Cause | 13 of 1,337 | 13 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Aspirin: Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events | 138 of 1,337 | 186 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Aspirin: serious adverse events | 372 of 1,337 | 433 of 1,335 | 2,672 | NCT00234065 | Trial comparisons |
| Cilostazol vs Clopidogrel: Number of Participants With Overall Cardiovascular Events | 15 of 232 | 10 of 225 | 457 | NCT00130039 | Trial comparisons |
| Cilostazol vs Clopidogrel: Number of Patients With Ipsilateral Ischemic Stroke Rate | 9 of 232 | 5 of 225 | 457 | NCT00130039 | Trial comparisons |
1 to 10 of 32
See all 32 comparisons in its trialsPapers from its trials163
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials10
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test A | 3 | 1 | ConductCognition |
| Trail Making Test B | 3 | 1 | ConductCognition |
| Stroop Color-Word Test | 2 | 1 | ConductCognition |
| Category Fluency | 1 | 0 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Selective Reminding Task | 1 | 0 | ConductCognition |
| Short Story Recall | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL799
GET https://conductscience.org/api/drugs/v1/CHEMBL799/diseases?page=2